Iolyx Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$15M
- Investors
-
4
Iolyx Therapeutics General Information
Description
Manufacturer of a clinical-stage company intending to transform the standard of care for ocular disease at the intersection of immunology and ophthalmology. The company's platform offers tailored formulations for precise local delivery of immunological drugs to relevant tissues, targeting ocular inflammation at its source, in the front and back of the eye, enabling clients efficacy, safety, and convenience.
Contact Information
Website
www.iolyx.comCorporate Office
- 1325 Howard Avenue
- Suite 904
- Burlingame, CA 94010
- United States
Corporate Office
- 1325 Howard Avenue
- Suite 904
- Burlingame, CA 94010
- United States
Iolyx Therapeutics Timeline
Iolyx Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 03-Dec-2025 | $15M | Completed | Clinical Trials - Phase 2 | ||
| 2. Early Stage VC (Series A) | 20-Apr-2023 | Completed | Generating Revenue | |||
| 1. Platform Creation | 01-Jan-2019 | Completed | Startup |
Iolyx Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Iolyx Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Iolyx Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Frazier Lifesciences Acquisition | Special Purpose Acquisition Company (SPAC) | Minority | ||
| GC&H Investments | Corporate Venture Capital | Minority | ||
| Alumni Ventures | Venture Capital | Minority | ||
| Frazier Healthcare Partners | PE/Buyout | Majority |
Iolyx Therapeutics FAQs
-
When was Iolyx Therapeutics founded?
Iolyx Therapeutics was founded in 2019.
-
Where is Iolyx Therapeutics headquartered?
Iolyx Therapeutics is headquartered in Burlingame, CA.
-
What is the size of Iolyx Therapeutics?
Iolyx Therapeutics has 4 total employees.
-
What industry is Iolyx Therapeutics in?
Iolyx Therapeutics’s primary industry is Drug Discovery.
-
Is Iolyx Therapeutics a private or public company?
Iolyx Therapeutics is a Private company.
-
What is the current valuation of Iolyx Therapeutics?
The current valuation of Iolyx Therapeutics is .
-
What is Iolyx Therapeutics’s current revenue?
The current revenue for Iolyx Therapeutics is .
-
How much funding has Iolyx Therapeutics raised over time?
Iolyx Therapeutics has raised $45M.
-
Who are Iolyx Therapeutics’s investors?
Frazier Lifesciences Acquisition, GC&H Investments, Alumni Ventures, and Frazier Healthcare Partners have invested in Iolyx Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
